ACNM supports National Coverage for $^{18}$NaF PET/CT

The Centers for Medicare & Medicaid Services (CMS) has reopened the national coverage policy on PET with sodium fluoride (NaF-18) to identify bone metastasis of cancer (CAG-00065R) and is seeking public comments on the proposal to end the coverage with evidence development (CED) requirement.

The American College of Nuclear Medicine is in support of the proposal by the National Oncologic PET Registry (NOPR) led by Drs. Bruce Hillner and Barry Siegel. The College agrees that the CED data collection and multiple publications on NaF-18 PET have demonstrated that NaF-18 PET is reasonable and necessary. We, therefore, support the lifting of the CMS CED requirement for national coverage for NaF PET/CT.

The College is working with American College of Radiology (ACR) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) in submitting joint formal comments to the CMS.

The College encourages its members to submit individual comments supporting the national coverage for NaF-18 PET, especially comments that include additional scientific evidence on the use of NaF PET for both malignant and benign bone diseases. The public comment period will remain open until April 15th, 2015.


Rathan M Subramaniam
President 2015